

Biomarker der Inflammation – Einsatz im klinischen Alltag?

Literatur

- [1] Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*, 2005. 352(16): p. 1685-95.
- [2] Ross, R., Atherosclerosis--an inflammatory disease. *N Engl J Med*, 1999. 340(2): p. 115-26.
- [3] WHO. 2. WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. 2001; Available from: <http://www.inchem.org/documents/ehc/ehc/ehc222.htm>.
- [4] Ait-Oufella, H., et al., Recent advances on the role of cytokines in atherosclerosis. *Arterioscler Thromb Vasc Biol*, 2011. 31(5): p. 969-79.
- [5] Ridker, P.M., Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. *Circ Res*, 2019. 124(3): p. 437-450.
- [6] Abbate, A., et al., Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. *Circ Res*, 2020. 126(9): p. 1260-1280.
- [7] Agostini, L., et al., NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. *Immunity*, 2004. 20(3): p. 319-25.
- [8] Ridker, P.M. and M. Rane, Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. *Circ Res*, 2021. 128(11): p. 1728-1746.
- [9] Pistrosch, F., et al., Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. *Diabetologia*, 2021. 64(12): p. 2701-2712.
- [10] Emerging Risk Factors, C., et al., C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med*, 2012. 367(14): p. 1310-20.
- [11] Ridker, P.M., et al., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*, 2000. 342(12): p. 836-43.
- [12] Glynn, R.J., J.G. MacFadyen, and P.M. Ridker, Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. *Clin Chem*, 2009. 55(2): p. 305-12.
- [13] Collaboration, I.R.G.C.E.R.F., et al., Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet*, 2012. 379(9822): p. 1205-13.
- [14] Ridker, P.M., et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*, 2008. 359(21): p. 2195-207.
- [15] Ridker, P.M., et al., Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med*, 2017. 377(12): p. 1119-1131.
- [16] Tardif, J.C., et al., Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med*, 2019. 381(26): p. 2497-2505.
- [17] Ravelli, R.B., et al., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature*, 2004. 428(6979): p. 198-202.
- [18] Lin, J.S., et al., Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*, 2018. 320(3): p. 281-297.
- [19] Visseren, F.L.J., et al., 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*, 2021. 42(34): p. 3227-3337.
- [20] Hanefeld, M., et al., The metabolic vascular syndrome - guide to an individualized treatment. *Rev Endocr Metab Disord*, 2016. 17(1): p. 5-17.
- [21] Vlachopoulos, C., et al., The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. *Atherosclerosis*, 2015. 241(2): p. 507-32.